128 related articles for article (PubMed ID: 34292217)
21. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
22. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.
van der Velden VH; van der Sluijs-Geling A; Gibson BE; te Marvelde JG; Hoogeveen PG; Hop WC; Wheatley K; Bierings MB; Schuurhuis GJ; de Graaf SS; van Wering ER; van Dongen JJ
Leukemia; 2010 Sep; 24(9):1599-606. PubMed ID: 20668473
[TBL] [Abstract][Full Text] [Related]
24. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
[TBL] [Abstract][Full Text] [Related]
25. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ
Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309
[TBL] [Abstract][Full Text] [Related]
26. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
27. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
[TBL] [Abstract][Full Text] [Related]
28. Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries.
Wennström L; Edslev PW; Abrahamsson J; Nørgaard JM; Fløisand Y; Forestier E; Gustafsson G; Heldrup J; Hovi L; Jahnukainen K; Jonsson OG; Lausen B; Palle J; Zeller B; Holmberg E; Juliusson G; Stockelberg D; Hasle H; ; ;
Pediatr Blood Cancer; 2016 Jan; 63(1):83-92. PubMed ID: 26281822
[TBL] [Abstract][Full Text] [Related]
29. DNA Methylation Adds Prognostic Value to Minimal Residual Disease Status in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Borssén M; Haider Z; Landfors M; Norén-Nyström U; Schmiegelow K; Åsberg AE; Kanerva J; Madsen HO; Marquart H; Heyman M; Hultdin M; Roos G; Forestier E; Degerman S
Pediatr Blood Cancer; 2016 Jul; 63(7):1185-92. PubMed ID: 26928953
[TBL] [Abstract][Full Text] [Related]
30. Measurable residual disease in pediatric acute myeloid leukemia: a systematic review.
Segerink WH; de Haas V; Kaspers GJL
Expert Rev Anticancer Ther; 2021 Apr; 21(4):451-459. PubMed ID: 33706635
[No Abstract] [Full Text] [Related]
31. Clinical and hematological correlates of aberrant immunophenotypic profiles in adult and pediatric acute myeloid leukemia at presentation.
Sharma M; Varma N; Singh Sachdeva MU; Bose P; Varma S
J Cancer Res Ther; 2020; 16(1):105-109. PubMed ID: 32362618
[TBL] [Abstract][Full Text] [Related]
32. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ
Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135
[TBL] [Abstract][Full Text] [Related]
33. [Clinical Study on Dynamic Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multiparameter Flow Cytometry].
Jin Y; Wang AY; Wang XB; Yang HZ; Liu X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):737-743. PubMed ID: 35680798
[TBL] [Abstract][Full Text] [Related]
34. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
35. Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study.
Tian H; Chen GH; Xu Y; Ma X; Chen F; Yang Z; Jin ZM; Qiu HY; Sun AN; Wu DP
Leuk Lymphoma; 2015 May; 56(5):1353-61. PubMed ID: 25204372
[TBL] [Abstract][Full Text] [Related]
36. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
Pettit K; Stock W; Walter RB
Leuk Lymphoma; 2016 Jul; 57(7):1527-33. PubMed ID: 27269126
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
38. Universal monitoring of minimal residual disease in acute myeloid leukemia.
Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
[TBL] [Abstract][Full Text] [Related]
39. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: evidence from four decades of US population data.
Hossain MJ; Xie L; Caywood EH
Cancer Epidemiol; 2015 Oct; 39(5):720-6. PubMed ID: 26159683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]